Upstate Announces Four New Agreements to Provide KinaseProfiler Servic

    Business Editors/Biotech Writers
    BIOWIRE2K

    ATLANTA--(BUSINESS WIRE)--Feb. 16, 2005--Serologicals Corporation (NASDAQ: SERO) today announced that Upstate Group, its wholly owned subsidiary, has entered into separate agreements to provide drug screening services to four companies -- Array Biopharma and three other significant multi-national pharmaceutical companies -- utilizing Upstate's KinaseProfiler(TM) service for determining selectivity and specificity of potentially therapeutic proprietary compounds.
    "More than 25% of new drugs being developed today are based on kinase technology," said Ian Ratcliffe, president of Upstate. "During 2004 alone we completed approximately 35 similar contracts with major life science companies." Upstate's share of the rapidly expanding global market of outsourced kinase screening services now exceeds 70%. Upstate's drug discovery business overall increased 42% in 2003 and 52% in 2004. The company's network of 300 cell signaling expert consultants is composed of key leaders in the field of drug discovery.
    KinaseProfiler(TM) provides quantitative characterization of compounds against a panel of 183 kinases in optimized assays. "That's significantly more than any other company can offer," said Ratcliffe, "and we expect to add over 100 new kinases to the panel in 2005." When KinaseProfiler(TM) was introduced in 2000, it was the first of its kind.
    Kinases play a critical role in the transmission of signals between and within cells. Aberrant or inappropriate kinase activity has been associated with as many as 400 diseases or conditions, including cancer, arthritis, diabetes, cardiovascular disease and neurological disorders. The KinaseProfiler(TM) service is being used primarily in cancer and inflammatory diseases research.
    Upstate is a leading research discovery provider of the highest quality cell signaling products and services to the life science market. Its customers are biomedical researchers at drug discovery companies and academic institutions in the key disciplines of oncology, immunology, proteomics, cardiology and neurology. Known for its enabling, innovative solutions to help understand the biology of kinases, chromatin, g-proteins and cytokines, Upstate's advanced cell biology tools - drug screening services, enzymes, state specific antibodies, siRNA kits, multiplex assays are used by thousands of customers worldwide, every day to accelerate improving human health. Upstate, a Serologicals company, is headquartered in Charlottesville, VA, with locations in Lake Placid, NY, and Dundee, Scotland.
    For more information, please visit our website www.upstate.com.

    Serologicals Corporation (NASDAQ: SERO), headquartered in Atlanta, GA, is a global leader in developing and commercializing consumable biological products, enabling technologies and services in support of biological research, drug discovery, and the bioprocessing of life-enhancing products. Our customers include researchers at major life science companies and leading research institutions involved in key disciplines, such as neurology, oncology, hematology, immunology, cardiology, proteomics, infectious diseases, cell signaling and stem cell research. In addition, Serologicals is the world's leading provider of monoclonal antibodies for the blood typing industry.
    Serologicals employs a total of more than 1,000 people worldwide in three Serologicals' companies: Chemicon International, headquartered in Temecula, CA, Upstate Group, LLC, headquartered in Charlottesville, VA and Celliance Corporation, headquartered in Atlanta, GA.
    For more information, please visit our website: www.serologicals.com.

    This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words or phrases such as "should result," "are expected to," "we anticipate," "we estimate," "we project" and similar expressions are intended to identify forward-looking statements. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements. These risks and uncertainties include, without limitation, our ability to increase the number of kinases that we offer to our screening customers.

    Serologicals is a registered trademark of Serologicals Royalty Company.

--30--LK/at*

CONTACT: Serologicals Corporation, Atlanta Bill Davis, 678/728-2018

KEYWORD: VIRGINIA GEORGIA INDUSTRY KEYWORD: BANKING BIOTECHNOLOGY SOURCE: Serologicals Corporation

Copyright Business Wire 2005